Dr. Demetri Explains the Side Effects of Regorafenib

George D. Demetri, MD
Published: Wednesday, Jun 20, 2012

George Demetri, MD, Director of the Ludwig Center and Sarcoma Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, explains the side effects associated with the oral multikinase inhibitor regorafenib, which targets the KIT and PDGFRA mutations while also blocking angiogenesis through dual VEGF receptor inhibition.

The side effects of regorafenib were assessed in a randomized phase III trial of 199 patients with gastrointestinal stromal tumors (GIST) that had developed a resistance to imatinib and sunitinib. Demetri notes that the side effects exhibited by regorafenib were similar to those seen with other multikinase inhibitors, especially those that prevent angiogenesis, such as the agent sunitinib, which is also used to treat GIST.

The two leading side effects associated with regorafenib were hand-foot syndrome and hypertension, which is a common adverse reaction for VEGF blocking agents. In general, Demetri notes that the side effects of regorafenib were similar to those seen with sunitinib and could be managed in the same fashion.
 
George Demetri, MD, Director of the Ludwig Center and Sarcoma Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, explains the side effects associated with the oral multikinase inhibitor regorafenib, which targets the KIT and PDGFRA mutations while also blocking angiogenesis through dual VEGF receptor inhibition.

The side effects of regorafenib were assessed in a randomized phase III trial of 199 patients with gastrointestinal stromal tumors (GIST) that had developed a resistance to imatinib and sunitinib. Demetri notes that the side effects exhibited by regorafenib were similar to those seen with other multikinase inhibitors, especially those that prevent angiogenesis, such as the agent sunitinib, which is also used to treat GIST.

The two leading side effects associated with regorafenib were hand-foot syndrome and hypertension, which is a common adverse reaction for VEGF blocking agents. In general, Demetri notes that the side effects of regorafenib were similar to those seen with sunitinib and could be managed in the same fashion.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x